Biotech M&A Deals Tops $15B in 2024
Learn which SD-based companies had billion-dollar acquisitions from buyers this year
Business San Diego delivers in-depth profiles of founders and insights on San Diego's most successful companies, executives, and technologies. Subscribe to make sure you don’t miss the next story.
M&A Deals Pick Up
Billions of dollars have traded in the private markets this year as large pharmaceutical companies are gradually regaining their interest in mergers and acquisitions.
Over the last twelve months, more than $15 billion has been spent buying-up some of the region’s most promising late-stage biotechnology firms — this number is slightly up from last year’s activity which saw fewer acquisitions across the board.
That includes DTx Pharma, which was acquired by Novartis for $1 billion and Prometheus Biosciences acquired by Merck for $10.8 billion in 2023.
There was more caution in the last year due to the high-rate environment and government policy uncertainty prior to the election. Mergers and acquisitions activity is expected to continue as the Federal Reserve continues to lower interest rates.
Below are the notable M&A biotech deals that made this year’s list.